Literature DB >> 31656559

Experience of adopting faecal immunochemical testing to meet the NICE colorectal cancer referral criteria for low-risk symptomatic primary care patients in Oxfordshire, UK.

Brian D Nicholson1, Tim James2, James E East3, David Grimshaw4, Maria Paddon2, Steve Justice2, Jason L Oke1, Brian Shine2.   

Abstract

OBJECTIVE: To compare the diagnostic performance of guaiac faecal occult blood (gFOB) testing with faecal immunochemical test (FIT) in a low-risk symptomatic primary care population to provide objective data on which to base local referral guidelines.
DESIGN: Stool samples from routine primary care practice sent for faecal occult blood testing were analysed by a standard gFOB method and the HM-JACKarc FIT between January and March 2016. Symptoms described on the test request were recorded. Patients were followed up over 21 months for evidence of serious gastrointestinal pathology including colorectal adenocarcinoma.
RESULTS: In 238 patients, the sensitivity and specificity for colorectal adenocarcinoma detection using gFOB were 85.7% and 65.8%, respectively, compared with 85.7% and 89.2% for FIT. The positive predictive value (PPV) for gFOB was 7.1% and negative predictive value (NPV) was 99.3%. Comparatively, the PPV for FIT was 19.4% and NPV 99.5%. The improved performance of FIT over gFOB was due to a lower false positive rate (10.8 vs 34.2, p≤0.01) with no increase in the false negatives rate. For any significant colorectal disease, the PPV for FIT increased to 35.5% with a reduction in NPV to 95.7%.
CONCLUSION: In this low-risk symptomatic patient group, the proportion of samples considered positive by FIT was considerably lower than gFOB with the same rate of colorectal adenocarcinoma detection. One in three of those with positive FIT had a significant colorectal disease. This supports National Institute of Health and Care Excellence recommendation that FIT can be reliably used as a triage test in primary care without overburdening endoscopy resources. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  colorectal cancer; guaiac test; primary care; stool markers

Year:  2018        PMID: 31656559      PMCID: PMC6788275          DOI: 10.1136/flgastro-2018-101052

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  19 in total

1.  Use of faecal occult blood tests in symptomatic patients.

Authors:  Robert Steele; Ian Forgacs; Gwyn McCreanor; Sally Benton; Michael Machesney; Colin Rees; Stephen P Halloran; Muti Abulafi; Deborah Alsina
Journal:  BMJ       Date:  2015-08-11

2.  Application of NICE guideline NG12 to the initial assessment of patients with lower gastrointestinal symptoms: not FIT for purpose?

Authors:  Aaron J Quyn; Robert Jc Steele; Jayne Digby; Judith A Strachan; Craig Mowat; Paula J McDonald; Francis A Carey; Ian M Godber; Hakim B Younes; Callum G Fraser
Journal:  Ann Clin Biochem       Date:  2017-06-29       Impact factor: 2.057

3.  Risk of Oral and Upper Gastrointestinal Cancers in Persons With Positive Results From a Fecal Immunochemical Test in a Colorectal Cancer Screening Program.

Authors:  Manon van der Vlugt; Esmée J Grobbee; Patrick M Bossuyt; Amanda C R K Bos; Ernst J Kuipers; Iris Lansdorp-Vogelaar; Manon C W Spaander; Evelien Dekker
Journal:  Clin Gastroenterol Hepatol       Date:  2018-02-07       Impact factor: 11.382

4.  Ileocolonic neuroendocrine tumours identified in the English bowel cancer screening programme.

Authors:  R Basuroy; C M O'Donnell; R Srirajaskanthan; J K Ramage
Journal:  Colorectal Dis       Date:  2018-04       Impact factor: 3.788

5.  The guaiacum test for occult blood in faeces.

Authors:  R H Wilkinson; W A Penfold
Journal:  Lancet       Date:  1969-10-18       Impact factor: 79.321

6.  Evaluation of sample stability for a quantitative faecal immunochemical test and comparison of two sample collection approaches.

Authors:  Samantha Mellen; Maria de Ferrars; Claire Chapman; Sarah Bevan; James Turvill; Daniel Turnock
Journal:  Ann Clin Biochem       Date:  2018-03-29       Impact factor: 2.057

Review 7.  Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

Authors:  Jennifer S Lin; Margaret A Piper; Leslie A Perdue; Carolyn M Rutter; Elizabeth M Webber; Elizabeth O'Connor; Ning Smith; Evelyn P Whitlock
Journal:  JAMA       Date:  2016-06-21       Impact factor: 56.272

8.  Diagnostic accuracy of faecal biomarkers in detecting colorectal cancer and adenoma in symptomatic patients.

Authors:  M M Widlak; C L Thomas; M G Thomas; C Tomkins; S Smith; N O'Connell; S Wurie; L Burns; C Harmston; C Evans; C U Nwokolo; B Singh; R P Arasaradnam
Journal:  Aliment Pharmacol Ther       Date:  2016-12-01       Impact factor: 8.171

9.  Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms.

Authors:  Craig Mowat; Jayne Digby; Judith A Strachan; Robyn Wilson; Francis A Carey; Callum G Fraser; Robert J C Steele
Journal:  Gut       Date:  2015-08-20       Impact factor: 23.059

10.  Is there an added value of faecal calprotectin and haemoglobin in the diagnostic work-up for primary care patients suspected of significant colorectal disease? A cross-sectional diagnostic study.

Authors:  Sjoerd G Elias; Liselotte Kok; Niek J de Wit; Ben J M Witteman; Jelle G Goedhard; Mariëlle J L Romberg-Camps; Jean W M Muris; Karel G M Moons
Journal:  BMC Med       Date:  2016-09-26       Impact factor: 8.775

View more
  7 in total

1.  Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC): a joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the British Society of Gastroenterology (BSG).

Authors:  Kevin J Monahan; Michael M Davies; Muti Abulafi; Ayan Banerjea; Brian D Nicholson; Ramesh Arasaradnam; Neil Barker; Sally Benton; Richard Booth; David Burling; Rachel Victoria Carten; Nigel D'Souza; James Edward East; Jos Kleijnen; Michael Machesney; Maria Pettman; Jenny Pipe; Lance Saker; Linda Sharp; James Stephenson; Robert Jc Steele
Journal:  Gut       Date:  2022-07-12       Impact factor: 31.793

2.  Faecal immunochemical test to triage patients with abdominal symptoms for suspected colorectal cancer in primary care: review of international use and guidelines.

Authors:  Marije van Melle; Samir I S Yep Manzano; Hugh Wilson; Willie Hamilton; Fiona M Walter; Sarah E R Bailey
Journal:  Fam Pract       Date:  2020-10-19       Impact factor: 2.267

3.  Recognising Colorectal Cancer in Primary Care.

Authors:  Natalia Calanzani; Aina Chang; Marije Van Melle; Merel M Pannebakker; Garth Funston; Fiona M Walter
Journal:  Adv Ther       Date:  2021-04-17       Impact factor: 3.845

4.  Faecal immunochemical test for patients with 'high-risk' bowel symptoms: a large prospective cohort study and updated literature review.

Authors:  Helga E Laszlo; Allan Hackshaw; Michael Machesney; Edward Seward; Ruth M Ayling; Jennifer Lake; Aman Malhi; Clare Stephens; Kathy Pritchard-Jones; Donna Chung
Journal:  Br J Cancer       Date:  2021-12-13       Impact factor: 7.640

5.  Combining faecal immunochemical testing with blood test results for colorectal cancer risk stratification: a consecutive cohort of 16,604 patients presenting to primary care.

Authors:  Diana R Withrow; Brian Shine; Jason Oke; Andres Tamm; Tim James; Eva Morris; Jim Davies; Steve Harris; James E East; Brian D Nicholson
Journal:  BMC Med       Date:  2022-03-15       Impact factor: 8.775

Review 6.  Colorectal Cancer Diagnosis: The Obstacles We Face in Determining a Non-Invasive Test and Current Advances in Biomarker Detection.

Authors:  Faddy Kamel; Khadiga Eltarhoni; Pasha Nisar; Mikhail Soloviev
Journal:  Cancers (Basel)       Date:  2022-04-08       Impact factor: 6.575

7.  Role of the faecal immunochemical test in patients with risk-stratified suspected colorectal cancer symptoms: A systematic review and meta-analysis to inform the ACPGBI/BSG guidelines.

Authors:  Richard Booth; Rachel Carten; Nigel D'Souza; Marie Westwood; Jos Kleijnen; Muti Abulafi
Journal:  Lancet Reg Health Eur       Date:  2022-10-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.